[
  {
    "ts": null,
    "headline": "Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?",
    "summary": "INCY heads into Q4 earnings with strong Jakafi sales, rising royalties and multiple new launches contributing to revenues, setting the stage for a potential upside surprise.",
    "url": "https://finnhub.io/api/news?id=ac497b6025230b39f459722971c3dfd060cb89b1cc6c2f80d7940dd8585dbdcb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770384180,
      "headline": "Incyte Gears Up to Report Q4 Earnings: Is a Beat in the Cards?",
      "id": 138375422,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "INCY heads into Q4 earnings with strong Jakafi sales, rising royalties and multiple new launches contributing to revenues, setting the stage for a potential upside surprise.",
      "url": "https://finnhub.io/api/news?id=ac497b6025230b39f459722971c3dfd060cb89b1cc6c2f80d7940dd8585dbdcb"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Incyte (INCY) Valuation After CHMP Backing For Zynyz In Anal Canal Cancer",
    "summary": "Incyte (INCY) is back in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on Zynyz plus platinum-based chemotherapy for first-line treatment of certain anal canal cancers. See our latest analysis for Incyte. That positive CHMP opinion lands at a time when Incyte’s shares, last closing at US$102.76, show a mixed picture, with a 7 day share price return of 2.69%, a 30 day share price return of 7.06% and a 1 year total...",
    "url": "https://finnhub.io/api/news?id=0f4d7439e575d2d10a62578e3c00a8f3288dd2e4cf0761557835ee1f05aed2d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770372318,
      "headline": "Assessing Incyte (INCY) Valuation After CHMP Backing For Zynyz In Anal Canal Cancer",
      "id": 138373712,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte (INCY) is back in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on Zynyz plus platinum-based chemotherapy for first-line treatment of certain anal canal cancers. See our latest analysis for Incyte. That positive CHMP opinion lands at a time when Incyte’s shares, last closing at US$102.76, show a mixed picture, with a 7 day share price return of 2.69%, a 30 day share price return of 7.06% and a 1 year total...",
      "url": "https://finnhub.io/api/news?id=0f4d7439e575d2d10a62578e3c00a8f3288dd2e4cf0761557835ee1f05aed2d4"
    }
  }
]